Skip Navigation


Issue No. 3 | February 10, 2017
A Service of the U.S. Department of Health and Human ServicesView HTML version
News and Features 

FDA Updates Evotaz, Stribild, and Sustiva Labeling

The Food and Drug Administration (FDA) recently approved changes to the Evotaz, Stribild, and Sustiva labeling. Click the links below to read the FDA press release for each drug:

  • Evotaz: The label was updated to include new clinical trial data and drug interaction information.
  • Stribild: The label was updated to expand the patient population to include pediatric patients 12 years of age and older weighing at least 35 kg. The Dosage and Administration, Warnings and Precautions, and Adverse Reactions sections of the label were updated with new information.
  • Sustiva: The Warnings and Precautions and Adverse Reactions sections of the label were updated to include information about catatonia.

The updated labeling will be available at the FDA website.

To learn more about these drugs, view the AIDSinfo patient fact sheets for Evotaz, Stribild, and Sustiva.

Home | Guidelines | Clinical Trials | Drugs | Health Topics | Education Materials | Mobile Resources & Tools
Contact Us
Left footer corner image Left footer corner image